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 Pterygium has long been considered to be a chronic de-
generative condition. However, after overexpression of the p53
protein was found in the epithelium of pterygium, some re-
searchers began to feel that pterygium was an ultraviolet (UV)-
related tumor rather than a degenerative disease [1-5].
The mechanism by which UV light induces uncontrolled
proliferation in pterygial cells is under investigation, but still
remains unclear. The noxious effects of UV irradiation are
moderated either directly by the UV phototoxic effect or indi-
rectly by the formation of radical oxygen species (ROS) [6,7].
ROS are harmful to cells, because they injure cellular pro-
teins, lipids, and DNA in a process known as oxidative stress
[6,7]. Moreover, ROS can induce cyclooxygenase 2 (COX 2)
formation via activation of the NF-kB signaling pathway [8].
Both ROS and COX 2 were found to play the most important
role in UV-related cutaneous carcinogenesis [6-11].
If pterygium is a UV-related uncontrolled cell prolifera-
tion, it is logical to assume that ROS and COX 2 may be found
in pterygium. Our previous research identified ROS and oxi-
dative stress in pterygium [12]; however, there is no report
about the presence of COX 2 in pterygium. If COX 2 is in-
deed expressed, it provides further evidence of UV-related un-
controlled cell proliferation.
To investigate whether COX 2 is present in pterygium,
we set out to evaluate COX 2 expression in pterygium. In this
study, COX 2 protein was studied immunohistochemically in
both pterygium and normal conjunctiva and limbus.
METHODS
 Informed consent was obtained from all individuals who par-
ticipated in this study. Primary pterygium samples were har-
vested from 90 patients undergoing pterygium surgery. These
were 51 males and 39 females, with an age range of 50-83
years and an average age of 64.2 years. Normal conjunctiva
samples were collected from medial conjunctiva of 22 patients
and superior conjunctiva of 18 patients without pterygium and
pinguecula when they underwent cataract or vitreoretinal sur-
gery. Five normal limbal specimens were collected from re-
sidual sclerocorneal rims in penetrating keratoplasty. The con-
trol group contained 26 males and 19 females, with an age
range of 55-81 years and a mean of 68.3 years. This study was
carried out with approval from the Human Study Committee
of the China Medical University Hospital and National Cheng
Kung University Hospital.
All specimens were fixed in formalin before being em-
bedded in paraffin. Briefly, 3 µm sections were cut, mounted
on glass, and dried overnight at 37 °C. All sections were then
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Purpose: Following the recent discovery of an abnormal expression of the p53 gene in the epithelium in pterygium, some
researchers felt that pterygium is a tumor rather than a degenerative disease. Ultraviolet (UV) radiation has been reported
to be associated with pterygium formation, however the mechanism whereby UV induces uncontrolled proliferation in
pterygial cells is unclear. Because cyclooxygenase 2 (COX 2) was reported to exist and play an important role in UV-
related cutaneous carcinogenesis, it is logical to suspect that COX 2 existed in pterygium. This study was designed to
investigate the expression of COX 2 in pterygium.
Methods: Immunohistochemical staining using a monoclonal antibody to COX 2 was performed on 90 pterygial speci-
mens, 40 normal conjunctiva, and 5 normal limbus.
Results: In the pterygium group, 75 (83.3%) specimens stained positive for COX 2. The staining was limited to the
cytoplasm of the epithelial layer and predominantly over the basal epithelial layer. No substantial staining was visible in
the subepithelial fibrovascular layers. All specimens were negative in the normal conjunctiva and limbus group.
Conclusions: The present study showed COX 2 existed in pterygium. Given the role of COX 2 in cutaneous tumor
carcinogenesis, we suggest COX 2 may also play a role in pterygium formation. This study could be used as the basis for
future surveys of the causal relationship between COX 2 and pterygium as well as the effect of COX 2 inhibitor in
preventing primary or recurrent pterygium.
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635deparaffinized in xylene, rehydrated with alcohol, and washed
in phosphate-buffered saline. This buffer was used for all sub-
sequent washes. Sections for COX 2 detection were heated in
a microwave oven twice for 5 min in citrate buffer (pH 6.0).
Mouse anti-COX 2 monoclonal antibody (at a dilution of
1:200; Alexis Biochemicals, San Diego, CA) was used as the
primary antibody The incubation time was 60 min at room
temperature followed by a conventional streptavidin peroxi-
dase method (LSAB Kit K675; DAKO, Glostrup, Denmark).
Signals were developed with 3, 3'-diaminobenzidine for 5 min
and counter-stained with hematoxylin. Negative controls were
obtained by leaving out primary antibody. COX 2 protein ex-
pression in colon cancer tissue was used as positive control.
Sections of paraffin-embedded colon cancer samples were
collected from the Chung Shan Medical University Hospital
(CSMUH) after obtaining written informed consent accord-
ing to a biology study approved by the CSMUH Institutional
Review Board. The histological diagnosis and clinic patho-
logical staging were according to the WHO classification. The
results were scored for the percentage of positive staining:
score 0, no positive staining; score +, from 1% to 10%; score
++, from 11% - 50%; score +++, more than 50% positive cells.
In this study, scores +, ++, and +++ were considered to be a
positive immunostaining, and score 0 was seen as a negative
immunostaining.
RESULTS
 There were 51 males and 39 females in the pterygium group
(age ranges from 50 to 83 years with an average of 64.2 years),
and 26 males and 19 females in the control group (age
range=55-81 years, mean=68.3 years).
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Figure 1. Immunohistochemical analysis of COX 2
protein expression in pterygium.  A: This panel shows
negative expression. Positive immunostaining of
scores +, ++, and +++ were showen in B, C, and D.
E: COX 2 protein expression in colon cancer tissue
was used as a positive control. COX 2 immunostaining
showed a brown reaction product, and COX 2 immu-
noreactive protein was seen predominantly over the
basal epithelial layer. No substantial staining was vis-
ible in the subepithelial fibrovascular layers. COX 2
staining was evident in cytoplasm and membrane of
the epithelial layer.
636In the pterygium group, the scores were as follows: 15
(16.7%) specimens were negative, 12 (13.3%) were +, 31
(34.4%) were ++, and 32 (35.6%) were +++. Seventy-five
(83.3%) specimens were positive for COX 2 staining (Figure
1). The COX 2 staining was shown in cytoplasm and mem-
brane of the epithelial layer and predominantly over the basal
epithelial layer. No substantial staining was visible in the sub-
epithelial fibrovascular layers. Goblet cells were intermingled
in 10 of 90 pterygial specimens, and all were positive for COX
2 immunoreaction. There were no significant differences in
sex and age between COX 2 positive and negative groups. In
the normal conjunctiva and limbus groups, all specimens were
negative for COX 2 staining (Figure 2).
DISCUSSION
 There are two distinct forms of cyclooxygenase: COX 1 and
COX 2. COX 1 is constitutively expressed in most tissues,
whereas COX 2 is inducible by a variety of tumor-promoting
agents, e.g. UV light [8-11,13]. A model has been proposed
regarding the role of COX 2 in UV-related skin cancer: (1) it
may serve to enhance prostaglandin E 2 production, which
may function as a mitogen in an initiated cell population; (2)
it may inhibit apoptosis and thus promote retention of UV-
induced “sunburn cells,” which are normally discarded by the
epidermis as apoptotic cells; (3) it may alter the ability of the
cells to attach to substrate and thus enhance their propensity
to exhibit tumorigenic growth; and (4) it may enhance the for-
mation of DNA adducts or decrease their repair [14,15]. Also,
COX 2 was reported to be a key enzyme for inflammatory
cytokine-induced angiogenesis, and the upregulation of vas-
cular endothelial growth factor, basic fibroblast growth fac-
tor, and nitric oxide synthases, which are associated with tu-
mor formation [16,17].
In our series, 83.3% of pterygial specimens had COX 2
expression while normal conjunctiva and limbus specimens
had no COX 2 expression, indicating COX 2 indeed only ex-
isted in pterygium and not in normal conjunctiva and limbus.
Moreover, the aforedescribed findings regarding the effects
of COX 2 in cutaneous tumor formation have also been re-
ported in pterygium, including disruption of apoptosis [3,18],
limbal epithelial proliferation [19], abnormal p53 gene expres-
sion [1-5], and upregulation of basic fibroblast growth factor
[20], vascular endothelial growth factor, and nitric oxide
synthases [21]. Hence, we suggest that COX 2 may play a
similar role in pterygium formation as that found in cutaneous
tumorigenesis. Karim et al. [22] discovered COX 2 positive
immunostaining in the cytoplasm and membranes in 96% (28
of 29 retinoblastoma patients) and in both differentiated and
undifferentiated retinoblastomas, but not in normal portions.
In our study, the similar staining pattern was also found. COX
2 had a positive immunoreaction in cytoplasm and membrane
of pterygical tissues but not in normal conjunctiva and lim-
bus. This may provide an indirect evidence that pterygium
may be a tumor.
In cutaneous tumorigenesis, the mechanism involving
COX 2 induced by UV irradiation was proposed to be via the
generation of ROS, so there was a pathway of UV- ROS-COX
2 in cutaneous tumor [11]. In our previous survey, there was
also oxidative DNA damage in pterygium, and lack of glu-
tathione S-transferase M1, one of the antioxidant defense en-
zymes, which was found to be associated with early onset
pterygium [12,23]. Hence, oxidative stress exists in pterygium.
Our present study provides further evidence that there may be
a similar pathway of UV-ROS-COX 2 in pterygium.
COX 2 is one of the key enzymes in the synthesis of pros-
taglandins. There is evidence to indicate that COX 2-induced
prostaglandin synthesis contributes to UV-induced cutaneous
tumorigenesis [9,10]. Hence, nonsteroidal antiinflammatory
drugs (NSAIDs) are effective in skin cancer prevention [9,10].
If this relationship also exists in pterygium formation, COX 2
inhibitors and NSAIDs may be alternatives to mitomycin C,
which has been widely used in pterygium but with several
sight-threatening complications [24,25]. Further studies are
necessary to evaluate the role of prostaglandins in pterygium
formation and the effect of COX 2 inhibitors and NSAIDs in
preventing primary and recurrent pterygium.
In conclusion, the present study shows that there is high
expression of COX 2 in pterygium. Given the role of COX 2
in cutaneous tumorigenesis, we suggest that COX 2 may play
a role in pterygium formation. This could serve as the basis of
future surveys of the causal relationship between COX 2 and
pterygium, the pathway of UV-ROS-COX 2- PGE 2 in ptery-
gium, and the effect of COX 2 inhibitors and NSAIDs in pre-
venting primary or recurrent pterygium.
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